Beam Therapeutics Inc.
BEAMNASDAQHealthcare● Active
$29.50
+$0.10(+0.34%)
Market Cap$3.0B
P/E Ratio—
52W High$36.44
52W Low$15.6
Beam Therapeutics Inc. (BEAM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BEAM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.91
Est. -$0.87 · -4.6%
Revenue
$0.03B
Est. $0.01B · +189.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
BEAM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$1.11 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.87 | -$0.91 | -4.6% | $0.03B | $0.01B | +189.1% |
| ▲ Q1 FY2026 | Feb 24, 2026 | -$1.13 | -$0.10 | +91.2% | $0.11B | $0.01B | +877.9% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.98 | -$1.10 | -12.2% | $0.01B | $0.01B | -26.6% |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$1.04 | -$1.00 | +3.9% | $0.01B | $0.01B | -26.6% |
| ▼ Q2 FY2025 | May 6, 2025 | -$1.11 | -$1.24 | -11.7% | $0.01B | $0.02B | -51.9% |
| ▲ Q1 FY2025 | Feb 25, 2025 | -$1.25 | -$1.09 | +12.8% | $0.03B | $0.02B | +82.5% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -$1.13 | -$1.17 | -3.5% | $0.01B | $0.02B | -5.6% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$1.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.91
EPS Est.
-$0.87
EPS Surpr.
-4.6%
Revenue
$0.03B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
-$0.10
EPS Est.
-$1.13
EPS Surpr.
+91.2%
Revenue
$0.11B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$1.10
EPS Est.
-$0.98
EPS Surpr.
-12.2%
Revenue
$0.01B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$1.00
EPS Est.
-$1.04
EPS Surpr.
+3.9%
Revenue
$0.01B
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$1.24
EPS Est.
-$1.11
EPS Surpr.
-11.7%
Revenue
$0.01B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
-$1.09
EPS Est.
-$1.25
EPS Surpr.
+12.8%
Revenue
$0.03B
Q4 FY2024
Nov 5, 2024Miss
EPS Actual
-$1.17
EPS Est.
-$1.13
EPS Surpr.
-3.5%
Revenue
$0.01B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-2.15 | $-1.09 | $-0.03 | 3 |
| Q3 FY2027 | $-2.17 | $-1.10 | $-0.03 | 4 |
| Q2 FY2027 | $-2.18 | $-1.11 | $-0.03 | 3 |
| Q1 FY2027 | $-2.18 | $-1.11 | $-0.03 | 3 |
| Q4 FY2026 | $-2.34 | $-1.19 | $-0.03 | 7 |
| Q3 FY2026 | $-1.27 | $-1.16 | $-1.03 | 9 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -4.6% | $32.34 | $31.47 | -2.69% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +91.2% | $28.33 | $32.29 | +13.98% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -12.2% | $24.25 | $22.74 | -6.23% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +3.9% | $19.12 | $18.70 | -2.20% |
| ▼ Q2 FY2025 | May 6, 2025 | -11.7% | $19.82 | $15.99 | -19.32% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +12.8% | $30.79 | $29.84 | -3.09% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -3.5% | $24.36 | $23.93 | -1.77% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +1.8% | $25.61 | $25.52 | -0.35% |
Q2 FY2026-2.69%
Report Date
May 7, 2026
EPS Beat/Miss
-4.6%
Price Before
$32.34
Price After
$31.47
Q1 FY2026+13.98%
Report Date
Feb 24, 2026
EPS Beat/Miss
+91.2%
Price Before
$28.33
Price After
$32.29
Q4 FY2025-6.23%
Report Date
Nov 4, 2025
EPS Beat/Miss
-12.2%
Price Before
$24.25
Price After
$22.74
Q3 FY2025-2.20%
Report Date
Aug 5, 2025
EPS Beat/Miss
+3.9%
Price Before
$19.12
Price After
$18.70
Q2 FY2025-19.32%
Report Date
May 6, 2025
EPS Beat/Miss
-11.7%
Price Before
$19.82
Price After
$15.99
Q1 FY2025-3.09%
Report Date
Feb 25, 2025
EPS Beat/Miss
+12.8%
Price Before
$30.79
Price After
$29.84
Q4 FY2024-1.77%
Report Date
Nov 5, 2024
EPS Beat/Miss
-3.5%
Price Before
$24.36
Price After
$23.93
Q3 FY2024-0.35%
Report Date
Aug 6, 2024
EPS Beat/Miss
+1.8%
Price Before
$25.61
Price After
$25.52
Avg Beat Reaction+2.09%
Avg Miss Reaction-7.50%
Beat Rate4 / 8 quarters
Largest Move-19.32% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BEAM ends December
Beam Therapeutics Inc. (BEAM) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.91 — missing the analyst consensus of $-0.87 by -4.6%. The next BEAM earnings date is expected around September 1, 2026.
Each quarter, investors track BEAM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BEAM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BEAM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BEAM earnings · 5 questionsBeam Therapeutics Inc.'s next earnings report is expected around September 1, 2026. BEAM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BEAM historically reports after market close (AMC).
BEAM earnings datewhen is BEAM earningsBEAM next earnings datewhen does BEAM report earningsBEAM earnings calendar
▸ Source: FMP · Beam Therapeutics Inc. SEC filings · US GAAP · Beam Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026